GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » Enterprise Value

Eton Pharmaceuticals (Eton Pharmaceuticals) Enterprise Value : $82.39 Mil (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Eton Pharmaceuticals's Enterprise Value is $82.39 Mil. Eton Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $0.54 Mil. Therefore, Eton Pharmaceuticals's EV-to-EBIT ratio for today is 152.01.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Eton Pharmaceuticals's Enterprise Value is $82.39 Mil. Eton Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $1.48 Mil. Therefore, Eton Pharmaceuticals's EV-to-EBITDA ratio for today is 55.60.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Eton Pharmaceuticals's Enterprise Value is $82.39 Mil. Eton Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $34.30 Mil. Therefore, Eton Pharmaceuticals's EV-to-Revenue ratio for today is 2.40.


Eton Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Eton Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals Enterprise Value Chart

Eton Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 121.21 183.51 97.93 61.71 96.53

Eton Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.02 73.80 90.71 96.53 84.70

Competitive Comparison of Eton Pharmaceuticals's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eton Pharmaceuticals's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's Enterprise Value falls into.



Eton Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Eton Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Eton Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eton Pharmaceuticals  (NAS:ETON) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Eton Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=82.392/0.542
=152.01

Eton Pharmaceuticals's current Enterprise Value is $82.39 Mil.
Eton Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.54 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Eton Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=82.392/1.482
=55.60

Eton Pharmaceuticals's current Enterprise Value is $82.39 Mil.
Eton Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.48 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Eton Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=82.392/34.304
=2.40

Eton Pharmaceuticals's current Enterprise Value is $82.39 Mil.
Eton Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $34.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eton Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Eton Pharmaceuticals (Eton Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.
Executives
David Krempa officer: Chief Business Officer 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen director, officer: President & CEO C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber officer: Chief Financial Officer 618 AMES STREET, LIBERTYVILLE IL 60048
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
William Wilson Troutman officer: CFO, Treasurer & Secretary 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc. 10 percent owner 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams director 5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum director C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121

Eton Pharmaceuticals (Eton Pharmaceuticals) Headlines